Companies › Guangdong Hengrui Pharmaceutical
12 active drug programs in 26 registered trials: 16 Phase 2, 5 Phase 1, 5 Phase 3; Immunology, Respiratory, Neurology, Genitourinary; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SHR-1819 Injection IL-4 receptor alpha inhibitor | IL4R | Phase 3 | Seasonal Allergic Rhinitis; Adolescents With Moderate-to-severe Atopic Dermatitis; Moderate-to-severe Atopic Dermatitis; Prurigo Nodularis | Dec 2026 |
| SHR-1905 IL-4 receptor alpha antagonist | – | Phase 3 | Asthma; Chronic Rhinosinusitis With Nasal Polyps; Moderate-to-severe Atopic Dermatitis | Feb 2027 |
| SHR-1703 Injection IL-5 receptor alpha antagonist | IL5RA | Phase 3 | Asthma With Eosinophilic Phenotype; Eosinophilic Asthma Patients; Eosinophilic Granulomatosis With Polyangiitis | Sep 2027 |
| HRS-9821 Inhalation Suspension | – | Phase 2 | COPD | Nov 2026 |
| SHR-2173 Injection | – | Phase 2 | Primary IgA Nephropathy; Active Lupus Nephritis; Primary Membranous Nephropathy; Generalized Myasthenia Gravis … | Nov 2026 |
| SHR-1139 injection | – | Phase 2 | Moderate to Severe Plaque Psoriasis; Psoriasis; Adult Patients With Moderately to Severely Active Ulcerative Colitis | Dec 2026 |
| HRS-9813 | – | Phase 2 | IPF and PPF | Jun 2028 |
| SHR-3045 Injection | – | Phase 2 | Moderate to Severe Active Rheumatoid Arthritis | – |
| SHR-7590 | – | Phase 1 | Moderate-to-severe Inflammatory Bowel Disease | Jan 2027 |
| SHR-7012 injection | – | Phase 1 | Cutaneous Lupus Erythematosus(CLE) | Apr 2027 |
| SHR-4712 | – | Phase 1 | Advanced Solid Tumor | May 2027 |
| HRS-9821 Powder for Inhalation | – | Phase 1 | COPD | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06875934 | SHR-1139 injection | Phase 2 | Moderate to Severe Plaque Psoriasis | Immunology | Nov 2025 |
| NCT07233655 | SHR-3045 Injection | Phase 2 | Moderate to Severe Active Rheumatoid Arthritis | Immunology | Apr 2026 |
| NCT07567872 | HRS-9821 Powder for Inhalation | Phase 1 | COPD | Respiratory | Sep 2026 |
| NCT07206758 | SHR-2173 Injection | Phase 1 | Immune Thrombocytopenia | Hematology | Nov 2026 |
| NCT07640451 | HRS-9821 Inhalation Suspension | Phase 2 | COPD | Respiratory | Nov 2026 |
| NCT07688772 | SHR-1819 Injection | Phase 3 | Seasonal Allergic Rhinitis | Immunology | Dec 2026 |
| NCT07719530 | SHR-1139 injection | Phase 2 | Psoriasis | Immunology | Dec 2026 |
| NCT07758101 | SHR-7590 | Phase 1 | Moderate-to-severe Inflammatory Bowel Disease | Immunology | Jan 2027 |
| NCT07211542 | SHR-1905 | Phase 2 | Moderate-to-severe Atopic Dermatitis | Immunology | Feb 2027 |
| NCT07354932 | SHR-2173 Injection | Phase 2 | Primary IgA Nephropathy | Genitourinary | Apr 2027 |
| NCT07749651 | SHR-7012 injection | Phase 1 | Cutaneous Lupus Erythematosus(CLE) | Immunology | Apr 2027 |
| NCT06993116 | SHR-4712 | Phase 1 | Advanced Solid Tumor | Oncology | May 2027 |
| NCT07229742 | SHR-2173 Injection | Phase 2 | Active Lupus Nephritis | Immunology | Jun 2027 |
| NCT07321951 | SHR-1819 Injection | Phase 2 | Moderate-to-severe Atopic Dermatitis | Immunology | Jun 2027 |
| NCT07289763 | SHR-2173 Injection | Phase 2 | Primary Membranous Nephropathy | Genitourinary | Aug 2027 |
| NCT07232576 | SHR-1139 injection | Phase 2 | Adult Patients With Moderately to Severely Active Ulcerative Colitis | Immunology | Aug 2027 |
| NCT07622342 | SHR-2173 Injection | Phase 2 | Generalized Myasthenia Gravis | Neurology | Sep 2027 |
| NCT06653322 | SHR-1703 Injection | Phase 3 | Asthma With Eosinophilic Phenotype | Respiratory | Sep 2027 |
| NCT07309055 | SHR-1819 Injection | Phase 3 | Adolescents With Moderate-to-severe Atopic Dermatitis | Immunology | Nov 2027 |
| NCT07098403 | SHR-1905 | Phase 3 | Asthma | Respiratory | Jan 2028 |
| NCT07299422 | SHR-2173 Injection | Phase 2 | Systemic Lupus Erythematosus | Immunology | Mar 2028 |
| NCT07132827 | SHR-1905 | Phase 3 | Chronic Rhinosinusitis With Nasal Polyps | Respiratory | Apr 2028 |
| NCT07192939 | HRS-9813 | Phase 2 | IPF and PPF | Respiratory | Jun 2028 |
| NCT06441812 | SHR-1703 Injection | Phase 2 | Eosinophilic Asthma Patients | Respiratory | Sep 2028 |
| NCT06554509 | SHR-1819 Injection | Phase 2 | Prurigo Nodularis | Immunology | Oct 2028 |
| NCT05979051 | SHR-1703 Injection | Phase 2 | Eosinophilic Granulomatosis With Polyangiitis | Immunology | Dec 2028 |
Sanofi Apogee Therapeutics Keymed Biosciences Co.Ltd Regeneron Pharmaceuticals Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Innovent Biologics (Suzhou) Uniquity One (UNI) Jiangsu Genscend Biopharmaceutical Genrix (Shanghai) Biopharmaceutical AstraZeneca
Apogee Therapeutics Sunshine Guojian Pharmaceutical (Shanghai) Jiangsu Genscend Biopharmaceutical Teva Branded Pharmaceutical Products R&D Prana Therapies
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.